07:00 , Oct 20, 2008 |  BC Week In Review  |  Clinical News

AVT-02 UE: Phase IIa data

A double-blind, placebo-controlled, German Phase IIa trial in 60 male patients with mild-to-moderate psoriasis showed that AVT-02 UE missed the primary endpoint of modified PASI score of marker plaques during a 4-week treatment. Avontec said...
07:00 , Jun 23, 2008 |  BC Week In Review  |  Clinical News

AVT-02 UE: Phase I data

In a double-blind, placebo-controlled, German Phase I trial in 20 healthy male volunteers, AVT-02 UE was well tolerated. There were no substantial changes of the skin physiology parameters and laboratory values. Patients received multiple doses...
07:00 , Mar 31, 2008 |  BioCentury  |  Product Development

Psoriasis pipeline

Psoriasis pipeline Company Product Route of administration Description Indication Status Medarex (NASDAQ:MEDX)/ Johnson & Johnson (NYSE:JNJ) Ustekinumab (CNTO 1275) Injection Human mAb against IL-12 and IL-23 Moderate to severe chronic plaque psoriasis Registration Johnson &...
08:00 , Mar 3, 2008 |  BC Week In Review  |  Clinical News

AVT-01: Phase IIa data

In a double-blind, U.K. and Romanian Phase IIa trial in 48 men with moderate asthma, once-daily AVT-01 missed the primary endpoint of a statistically significant reduction vs. placebo in bronchial hyper-responsiveness after methacholine challenge at...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Clinical News

AVT-02 UE: Phase I started

Avontec began a German Phase I trial to evaluate multiple doses of AVT-02 UE vs. placebo or physiological saline in 20 healthy male volunteers for 4 weeks. The company also is conducting a Phase IIa...
07:00 , Oct 8, 2007 |  BC Week In Review  |  Company News

Avontec board of directors update

Avontec GmbH , Martinsried, Germany   Business: Autoimmune, Inflammation, Cardiovascular   Appointed: Ernst Guenter Afting as chairman, former president and CEO of the GSF National Research Center for Environment and Health; and Miki Nakamori, director...
07:00 , Oct 1, 2007 |  BC Week In Review  |  Company News

Avontec management update

Avontec GmbH , Martinsried, Germany   Business: Inflammation, Autoimmune, Cardiovascular   Hired: Helga Grupe as CBO and managing director, formerly VP of business development at Wilex AG  ...
08:00 , Nov 20, 2006 |  BC Week In Review  |  Clinical News

AVT-01: Phase IIa started

Avontec started a Phase IIa trial to treat asthma. Avontec GmbH , Martinsried, Germany   Product: AVT-01   Business: Inflammation   Molecular target: Signal transducer and activator of transcription 1 (STAT1)   Description: Decoy oligonucleotide...
08:00 , Feb 6, 2006 |  BioCentury  |  Product Development

Emerging asthma treatments

Emerging asthma treatments Company Product Description Target Status Genentech/Tanox/ Novartis Xolair omalizumab Humanized MAb against IgE IgE Mkt (adults/ adolescents); Ph III(pediatric) Altana Daxas roflumilast Phosphodiesterase-4 (PDE-4) inhibitor PDE-4 Ph III; MAA withdrawn in Nov...
07:00 , Aug 15, 2005 |  BC Week In Review  |  Company News

Avontec board of directors update

Avontec GmbH , Martinsried, Germany   Business: Cardiovascular, Inflammation   Appointed: Lee Cheng Liu, COO of AnGes MG Inc.; Hongzhi Bai, an industry consultant; Markus Hosang, managing partner at BioMedinvest; and Joerg Neermann, managing partner...